Clinical Application of Detecting Immunoglobulin Heavy Chain Rearrangement in Plasma DNA of Patients with Bcell Malignancies

李洁,徐兵,宋小燕,陈国枢,周淑芸

DOI: https://doi.org/10.3969/j.issn.1001-9448.2008.04.019

2008-01-01

Abstract:Objective To evaluate the significance of detecting immunoglobulin heavy chain(IgH) gene rearrangement in plasma DNA of patients with B-cell malignancies.Methods DNA was extracted from plasma samples collected from 83 patients with B-acute lymphoblastic leukemia(B-ALL),B non-hodgkin′s lymphoma(B-NHL) and multiple myeloma(MM) patients,IgH gene rearrangement was detected by polymerase chain reaction(PCR) amplification.Results 77.8% patients with de novo B-cell malignancies were found with IgH gene rearrangement in plasma DNA sample.Among B-cell malignancies in complete remission(CR),only 27.6% of plasma DNA samples were detected with IgH gene rearrangement,which was significantly lower than that of de novo patients(P0.01).IgH gene rearrangement were not detected in Plasma samples with connective tissue disease,infectious patients and healthy donors.There was no statistical correlation between IgH gene rearrangement and clinical staging,β2-microglobulin(β2-MG)levels or lactic dehydrogenase(LDH) levels.Follow-up studies showed a close correlation of IgH gene rearrangement with disease states.Twelve patients turned PCR negative in plasma when they reached clinical CR after chemotherapy but turned positive 6 to 9 months later.These 3 cases all suffered clinical relapse later.IgH gene rearrangement turned positive 1 to 4 months before the relapse.One patient who had positive results in diagnosis and CR turned PCR negative after allogeneic hematopoietic stem cell transplantation.Three patients who were repeatedly positive for IgH rearrangement showed refractory response and a poor prognosis.Conclusion IgH gene rearrangement can be detected in plasma DNA in newly diagnosed patients with B-cell malignancies and has high positive rate and specificity.It can be used as a useful parameter for development of noninvasive diagnostic,prognostic and follow-up tests for malignancies.